Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation

Trends in Molecular Medicine

Volumn 13, Issue 12, 2007, Pages 503-511

  Lymperopoulos, Anastasios ^a   Rengo, Giuseppe ^a   Koch, Walter J ^a  

^a Center for Translational Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CATECHOLAMINE; DOXAZOSIN; G PROTEIN COUPLED RECEPTOR; METOPROLOL; MOXONIDINE; PRAZOSIN; XAMOTEROL;

ADRENAL GLAND; CATECHOLAMINE RELEASE; CLINICAL TRIAL; ENZYME REGULATION; HEART FAILURE; HEART STIMULATION; HUMAN; NONHUMAN; PROTEIN FUNCTION; REVIEW; SYMPATHETIC TONE;

HEART FAILURE; HUMANS; RECEPTORS, ADRENERGIC;

EID: 36249021393     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.10.005     Document Type: Review

References (89)

1. American Heart Association Heart and Stroke Statistical Update. (2001) Dallas, Texas: American Heart Association
2. Cohn J.N., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311 (1984) 819-823
3. Port J.D., and Bristow M.R. Altered β-adrenergic receptor gene regulation and signaling in chronic heart failure. J. Mol. Cell. Cardiol. 33 (2001) 887-905
4. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353 (1999) 2001-2007
5. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 353 (1999) 9-13
6. Packer M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334 (1996) 1349-1355
7. Bylund D.B., et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46 (1994) 121-136
8. Pierce K.L., et al. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3 (2002) 639-650
9. 2-adrenergic receptor subtypes b and c. Science 273 (1996) 803-805
10. MacMillan L.B., et al. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 273 (1996) 801-803
11. Hein L., et al. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402 (1999) 181-184
12. 2-adrenoceptor subtypes. Mol. Endocrinol. 17 (2003) 1640-1646
13. 2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 18 (1997) 211-219
14. Philipp M., et al. Placental alpha(2)-adrenoceptors control vascular development at the interface between mother and embryo. Nat. Genet. 31 (2002) 311-315
15. Bristow M.R. Mechanistic and clinical rationales for using beta-blockers in heart failure. J. Card. Fail. 6 (2000) 8-14
16. Philipp M., and Hein L. Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. Pharmacol. Ther. 101 (2004) 65-74
17. Philipp M., et al. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 (2002) R287-R295
18. Brede M., et al. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 106 (2002) 2491-2496
19. Brum P.C., et al. Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H1838-H1845
20. Small K.M., et al. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 381-411
21. Small K.M., et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347 (2002) 1135-1142
22. Small K.M., et al. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J. Biol. Chem. 275 (2000) 23059-23064
23. Neumeister A., et al. Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoceptor gene polymorphism in healthy humans. Pharmacogenet. Genomics 15 (2005) 143-149
24. Hoffman B.B., and Taylor P. Neurotransmission: the autonomic and somatic motor nervous system. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 10th edn (2001), McGraw-Hill 115-154
25. Young J.B., and Landsberg L. Catecholamines and the adrenal medulla. In: Wilson J.D., Foster D.W., Kronenberg H.M., and Larsen P.R. (Eds). Williams Textbook of Endocrinology. 9th edn (1998), W.B. Saunders 665-728
26. Eaton M.J., and Duplan H. Useful cell lines derived from the adrenal medulla. Mol. Cell. Endocrinol. 228 (2004) 39-52
27. Foucart S., et al. Modulation by beta-adrenoceptors and angiotensin II receptors of splanchnic nerve evoked catecholamine release from the adrenal medulla. Can. J. Physiol. Pharmacol. 69 (1991) 1-7
28. Foucart S., et al. In vivo interactions between prejunctional alpha 2- and beta 2-adrenoceptors at the level of the adrenal medulla. Can. J. Physiol. Pharmacol. 66 (1988) 1340-1343
29. Foucart S., et al. Local modulation of adrenal catecholamines release by beta-2 adrenoceptors in the anaesthetized dog. Naunyn Schmiedebergs Arch. Pharmacol. 337 (1988) 29-34
30. Lymperopoulos A., et al. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13 (2007) 315-323
31. Berkowitz D.E., et al. Localization of messenger RNA for three distinct alpha 2-adrenergic receptor subtypes in human tissues. Evidence for species heterogeneity and implications for human pharmacology. Anesthesiology 81 (1994) 1235-1244
32. Duzic E., and Lanier S.M. Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. III. Coupling of alpha 2-adrenergic receptor subtypes in a cell type-specific manner. J. Biol. Chem. 267 (1992) 24045-24052
33. Lymperopoulos A., et al. Alpha2-adrenergic receptor subtype-specific activation of NF-κB in PC12 cells. Neurosci. Lett. 402 (2006) 210-215
34. Zaika O.L., et al. Acetylcholine-induced calcium signalling in adrenaline- and noradrenaline-containing adrenal chromaffin cells. Arch. Biochem. Biophys. 424 (2004) 23-32
35. Yoshimura R., et al. Nicotinic and muscarinic acetylcholine receptors are essential for the long-term response of tyrosine hydroxylase gene expression to chronic nicotine treatment in rat adrenal medulla. Brain Res. Mol. Brain Res. 126 (2004) 188-197
36. Armando I., et al. Angiotensin II AT1 and AT2 receptor types regulate basal and stress-induced adrenomedullary catecholamine production through transcriptional regulation of tyrosine hydroxylase. Ann. N. Y. Acad. Sci. 1018 (2004) 302-309
37. Jezova M., et al. Angiotensin II AT(1) and AT(2) receptors contribute to maintain basal adrenomedullary norepinephrine synthesis and tyrosine hydroxylase transcription. Endocrinology 144 (2003) 2092-2101
38. Wallace D.J., et al. Histamine promotes excitability in bovine adrenal chromaffin cells by inhibiting an M-current. J. Physiol. 540 (2002) 921-939
39. Kobayashi H., et al. Pathophysiological function of adrenomedullin and proadrenomedullin N-terminal peptides in adrenal chromaffin cells. Hypertens. Res. 26 (2003) S71-S78
40. Moura E., et al. Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br. J. Pharmacol. 149 (2006) 1049-1058
41. Tseng C.J., et al. Modulation of catecholamine release by endogenous adenosine in the rat adrenal medulla. J. Biomed. Sci. 8 (2001) 389-394
42. Reiter E., and Lefkowitz R.J. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17 (2006) 159-165
43. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53 (2001) 1-24
44. Arriza J.L., et al. The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain. J. Neurosci. 12 (1992) 4045-4055
45. Rockman H.A., et al. Seven-transmembrane-spanning receptors and heart function. Nature 415 (2002) 206-212
46. Hata J.A., and Koch W.J. Phosphorylation of G protein-coupled receptors: GPCR kinases in heart disease. Mol. Interv. 3 (2003) 264-272
47. Petrofski J.A., and Koch W.J. The beta-adrenergic receptor kinase in heart failure. J. Mol. Cell. Cardiol. 35 (2003) 1167-1174
48. Penn R.B., et al. Regulation of G protein-coupled receptor kinases. Trends Cardiovasc. Med. 10 (2000) 81-89
49. Jewell-Motz E.A., and Liggett S.B. G protein-coupled receptor kinase specificity for phosphorylation and desensitization of alpha2-adrenergic receptor subtypes. J. Biol. Chem. 271 (1996) 18082-18087
50. Kurose H., and Lefkowitz R.J. Differential desensitization and phosphorylation of three cloned and transfected alpha 2-adrenergic receptor subtypes. J. Biol. Chem. 269 (1994) 10093-10099
51. Lembo P.M., et al. Receptor selectivity of the cloned opossum G protein-coupled receptor kinase 2 (GRK2) in intact opossum kidney cells: role in desensitization of endogenous alpha2C-adrenergic but not serotonin 1B receptors. Mol. Endocrinol. 13 (1999) 138-147
52. DeGraff J.L., et al. Role of arrestins in endocytosis and signaling of alpha2-adrenergic receptor subtypes. J. Biol. Chem. 274 (1999) 11253-11259
53. Shiina T., et al. Interaction with beta-arrestin determines the difference in internalization behavior between beta1- and beta2-adrenergic receptors. J. Biol. Chem. 275 (2000) 29082-29090
54. DeGraff J.L., et al. The third intracellular loop of alpha 2-adrenergic receptors determines subtype specificity of arrestin interaction. J. Biol. Chem. 277 (2002) 43247-43252
55. Cayla C., et al. Homologous regulation of the α2C-adrenoceptor subtype in human hepatocarcinoma, HepG2. Br. J. Pharmacol. 126 (1999) 69-78
56. Iaccarino G., et al. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation 98 (1998) 1783-1789
57. Ebert S.N., et al. Targeted insertion of the Cre-recombinase gene at the phenylethanolamine n-methyltransferase locus: a new model for studying the developmental distribution of adrenergic cells. Dev. Dyn. 231 (2004) 849-858
58. Floras J.S. The "unsympathetic" nervous system of heart failure. Circulation 105 (2002) 1753-1755
59. Arnlöv J., and Vasan R.S. Neurohormonal activation in populations susceptible to heart failure. Heart Fail. Clin. 1 (2005) 11-23
60. Anavekar N.S., and Solomon S.D. Angiotensin II receptor blockade and ventricular remodelling. J. Renin Angiotensin Aldosterone Syst. 6 (2005) 43-48
61. Zolk O., et al. Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats. Cardiovasc. Res. 53 (2002) 363-367
62. Zolk O., et al. Expression of endothelin-1, endothelin-converting enzyme, andendothelin receptors in chronic heart failure. Circulation 99 (1999) 2118-2123
63. Aggarwal A., et al. Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J. Am. Coll. Cardiol. 37 (2001) 1246-1251
64. Lang C.C., et al. Sympathoinhibitory response to clonidine is blunted in patients with heart failure. Hypertension 30 (1997) 392-397
65. Swedberg K., et al. The effects of moxonidine SR, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105 (2002) 1797-1803
66. Swedberg K., et al. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure: moxonidine investigators. J. Am. Coll. Cardiol. 35 (2000) 398-404
67. Koch W.J. Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure. Mol. Cell. Biochem. 263 (2004) 5-9
68. Tevaearai H.T., and Koch W.J. Molecular restoration of beta-adrenergic receptor signaling improves contractile function of failing hearts. Trends Cardiovasc. Med. 14 (2004) 252-256
69. Schlaich M.P., et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 43 (2004) 169-175
70. Schlaich M.P., et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108 (2003) 560-565
71. Foley C.M., et al. Thyroid status influences baroreflex function and autonomic contributions to arterial pressure and heart rate. Am. J. Physiol. Heart Circ. Physiol. 280 (2001) H2061-H2068
72. DeQuattro V., and Li D. Sympatholytic therapy in primary hypertension: a user friendly role for the future. J. Hum. Hypertens. 16 (2002) S118-S123
73. Bravo E.L. Pheochromocytoma. Cardiol. Rev. 10 (2002) 44-50
74. Wong M.L., et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 325-330
75. Charney D.S., et al. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am. J. Psychiatry 144 (1987) 1030-1036
76. Cheok F., et al. Identification, course, and treatment of depression after admission for a cardiac condition: rationale and patient characteristics for the identifying depression as a comorbid condition (IDACC) project. Am. Heart J. 46 (2003) 978-984
77. Takeda M., et al. Modulation of ACh-induced currents in rat adrenal chromaffin cells by ligands of α2 adrenergic and imidazoline receptors. Auton. Neurosci. 88 (2001) 151-159
78. The Cardiac Insufficiency Bisoprolol Study Group. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 353 (1999) 9-13
79. The Metoprolol, CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353 (1999) 2001-2007
80. Waagstein F., et al. For the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy (MDC) trial. Lancet 342 (1993) 1441-1446
81. Packer M., et al. For the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344 (2001) 1651-1658
82. Packer M., et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334 (1996) 1349-1355
83. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator β-blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation 52 (1995) 212-218
84. Poole-Wilson P.A., et al. For the Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomized controlled trial. Lancet 362 (2003) 7-13
85. The β-Blocker Evaluation of Survival Trial Investigators. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344 (2001) 1659-1667
86. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 336 (1990) 1-6
87. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. J. Am. Med. Assoc. 283 (2000) 1967-1975
88. Loeb H.S., et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA cooperative studies group. Circulation 87 (1993) VI78-VI87
89. Cohn, J.N. Presentation at Heart Failure '99. Goetheborg, Sweden, 5-8 June 1999